结直肠癌（colorectal cancer，CRC）的全球患病率日益增加，尽管相关治疗研究取得了一定进展，但由于存在耐药、有效率低等问题，结直肠癌的死亡率仍位居前3。越来越多的证据表明，黄芩的提取物黄芩苷及黄芩素作为新型小分子抑制剂，不仅具有良好的抗CRC作用，且不易诱导癌细胞产生耐药性。对黄芩苷及黄芩素这2种黄酮类化合物在CRC治疗中的研究现状进行系统综述，回顾和讨论了其在抑制癌细胞增殖及侵袭转移、诱导癌细胞死亡、调节肿瘤微环境（tumor microenvironment，TME）等方面的潜在作用及相关机制，以期为CRC的治疗方案提供新思路。

The prevalence of colorectal cancer (CRC) is increasing globally, and despite some advances were got in related treatments, CRC still ranks among the top three in terms of mortality rate due to the problems of drug resistance and low efficiency. There is increasing evidence that baicalin and baicalein, extracts of the traditional Chinese medicine Scutellaria baicalensis, as novel small-molecule inhibitors, not only have good anticolorectal cancer effects, but also are not easy to induce drug resistance in cancer cells. In this paper, a systematic review of the current research status of baicalin and baicalein, two flavonoids, in the treatment of colorectal cancer was presented, reviewing and discussing their potential roles and related mechanisms in inhibiting the proliferation and invasion and metastasis of cancer cells, inducing the death of cancer cells, and regulating the tumour microenvironment (TME), with the aim of providing new ideas for the therapeutic protocols of CRC.

R286.2

四川省科技厅自然科学基金青年项目（2023NSFSC1830）